GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Mycotopia Therapies Inc (OTCPK:TPIA) » Definitions » COGS-to-Revenue

Mycotopia Therapies (Mycotopia Therapies) COGS-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Mycotopia Therapies COGS-to-Revenue?

Mycotopia Therapies's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was $0.00 Mil.

Mycotopia Therapies's COGS to Revenue for the three months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Mycotopia Therapies's Gross Margin % for the three months ended in Dec. 2023 was N/A%.


Mycotopia Therapies COGS-to-Revenue Historical Data

The historical data trend for Mycotopia Therapies's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mycotopia Therapies COGS-to-Revenue Chart

Mycotopia Therapies Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial - - - - -

Mycotopia Therapies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Mycotopia Therapies COGS-to-Revenue Calculation

Mycotopia Therapies's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

Mycotopia Therapies's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mycotopia Therapies  (OTCPK:TPIA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Mycotopia Therapies's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Mycotopia Therapies COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mycotopia Therapies's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Mycotopia Therapies (Mycotopia Therapies) Business Description

Traded in Other Exchanges
N/A
Address
18851 NE 29th Avenue, Suite 700, Aventura, FL, USA, 33180
Mycotopia Therapies Inc provides psychedelic therapies through technology-focused, data-driven, and medical-based solutions for people dealing with anxiety, depression, bipolar disorders, PTSD, ADHD, autism, and addictions.
Executives
Mark D. Williams director, 10 percent owner, officer: President, CEO & CFO 480 22ND STREET, BOX 2, HEYBURN ID 83336
Gibson Colin director, 10 percent owner, officer: Vice President 480 22ND STREET, BOX 2, HEYBURN ID 83336

Mycotopia Therapies (Mycotopia Therapies) Headlines

From GuruFocus

Ehave Shareholder from CEO Ben Kaplan and Corporate Update

By Value_Insider Value_Insider 12-07-2022

Ehave Issues Shareholder Letter and Provides Corporate Update

By GuruFocusNews GuruFocusNews 01-31-2022